Publication AWA
At the Public Information Bulletin of the Agency for Health Technology Assessment and Tarification (AWA) has published reviews analyses for the evaluation of reimbursement applications:
- Givlaari (givosiran) for the treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older
- Tevimbra (tislelizumab) for the treatment of patients with lung cancer and pleural mesothelioma in the first line of NDRP
- Tevimbra (tislelizumab) for the treatment of patients with lung cancer and pleural mesothelioma in subsequent lines of treatment
- Rybrevant (amivantamab) for the treatment of patients with lung cancer and pleural mesothelioma
- Rybrevant (amivantamab) for the treatment of patients with lung cancer and pleural mesothelioma
- Lazcluze (lazertinib) for the treatment of patients with lung cancer and pleural mesothelioma
We encourage you to read the full documents and submit comments within the prescribed period of 7 days from the date of publication.
